Processa Pharmaceuticals, Inc.

Listed Company

PCSACIK 0001533743NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

—

Total Assets

—

Equity

—

Shares Out

2.75M

Op. Cash Flow

$-11.39M

PCSA$2.30+993.16% · past yearDBEQ Basic

Daily closing prices

Business

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Cancer therapies designed to improve safety and efficacy of established cancer drugs by modifying their metabolism and distribution. The company's lead candidate NGC-Cap combines PCS6422 with capecitabine for advanced breast cancer in Phase 2 trials. Processa also holds non-oncology assets for gastroparesis and glomerular disease being explored for out-licensing. The company operates globally and relies on contract manufacturing organizations for supply.

Summary from 10-K filed 2026-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development expenses	8	7	6	11	7
General and administrative expenses	6	5	6	9	5
Operating Loss	−14	−12	−11	−28	−12
Other income	20,000	—	—	—	—
Unrealized gain on digital assets at fair value	295,180	—	—	—	—
Interest and dividend income, net	109,491	201,088	335,541	101,202	11,627
Net Operating Loss Before Income Tax Benefit	−14	−12	−11	−27	−12
Income Tax Benefit	—	—	—	—	530,611
Net Loss	−14	−12	−11	−27	−11
Net Loss Per Common Share - Basic	−10.36	−96.78	−8.48	−34.05	−0.75
Net Loss Per Common Share - Diluted	−10.36	−96.78	−8.48	−34.05	—
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic	1	122,438	1	805,477	15
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted	1	122,438	1	805,477	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	6	1	5	7	16
Prepaid expenses and other	133,919	687,829	926,300	2	2
Total Current Assets	6	2	6	8	18
Digital assets at fair value	1	—	—	—	—
Prepaid expenses	993,701	1	—	—	—
Equipment, net	3,812	5,016	2,554	—	—
Operating lease right-of-use assets, net	—	70,677	146,057	227,587	74,181
Total Assets	8	3	6	9	26
Current maturities of lease liability	—	73,020	83,649	—	—
Accounts payable	1	880,880	311,617	327,548	218,905
Accrued expenses	1	578,731	146,274	403,061	279,265
Total Current Liabilities	2	2	730,579	998,556	971,020
Non-current lease liability	—	487	66,905	—	—
Total Liabilities	2	2	797,484	1	978,405
Commitments and Contingencies	—	—	—	—	—
Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at December 31, 2025 or 2024	—	—	—	—	—
Common stock, par value $0.0001, 1,000,000,000 shares authorized; 2,572,114 issued and 2,571,914 outstanding at December 31, 2025 and 148,308 issued and 148,108 outstanding at December 31, 2024	257	15	129	80	1,571
Additional paid-in capital	107	89	81	72	62
Treasury stock, 200 shares at cost	−300,000	−300,000	−300,000	−300,000	—
Accumulated deficit	−101	−87	−75	−64	−37
Total Stockholders Equity	6	2	5	7	25
Total Liabilities and Stockholders Equity	8	3	6	9	26

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	1,204	782	222	—	484
Non-cash lease expense for right-of-use assets	70,677	87,184	81,530	—	—
Stock-based compensation	857,550	629,514	1	9	3
Prepaid expenses and other	834,651	−1	956,834	210,549	−1
Operating lease liability	−66,905	−83,649	−78,896	−87,937	−87,200
Accounts payable	175,916	569,263	−15,931	108,643	−101,789
Due from related parties	—	−39	−12	—	—
Accrued expenses	600,726	432,457	−256,787	243,796	−65,049
Net cash used in operating activities	−11	−11	−8	−10	−9
Purchase of digital asset	−850,000	—	—	—	—
Purchase of equipment	—	−3,244	—	—	—
Net cash used in investing activities	−850,000	−3,244	−2,776	—	—
Net proceeds from issuance of common stock	17	8	6	—	10
Shares withheld to pay taxes on stock-based compensation	−10,404	−15,902	—	−88,843	−64,396
Settlement of stock award	—	−8,561	−52,746	—	—
Payment of finance lease obligation	−6,602	−5,202	—	—	—
Net cash provided by financing activities	17	8	6	−388,843	10
Net Increase (Decrease) in Cash and Cash Equivalents	4	−4	−2	−10	1
Cash paid for interest	5,607	1,204	—	—	—
Cash paid for income taxes	—	—	—	—	—
Issuance of 200 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor	—	189,000	—	400,000	400,000
Right-of-use asset obtained in exchange for financing lease liability	—	11,804	—	—	—
Financing lease liability	—	−11,804	—	—	—
Net	—	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Processa Pharmaceuticals, Inc.'s CIK number?

Processa Pharmaceuticals, Inc.'s SEC CIK number is 0001533743 (1533743). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Processa Pharmaceuticals, Inc.'s SEC filings?

All of Processa Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →